IMMUNOTECHOLOGIES CORE

当胃肠道生物学和疾病中心最初成立时， 重点分析上皮运输、生长、发育和修复，包括控制 这些功能由上皮下免疫细胞和间充质细胞发挥。从一开始， 核心设施能够测量可溶性信号分子（如肽）的水平， 激素、生长因子、类二十烷酸、细胞因子和环核苷酸）对于 研究人员正在努力实现这些目标。因此，建立了免疫测定（IA）核心， 配备一名核心主管（Don Powell博士）和一名核心技术员。1991年，迈克尔·戈伊博士 接替鲍威尔博士成为内部审计中心主任由于对核心服务的需求稳步增长， 2002年又雇用了一名半职技术员。 2008年1月，Scott Plevy取代Michael Goy成为IT核心总监。战略原因 Plevy博士在细胞因子生物学和定量技术方面的专业知识， 在历史上包括了核心的主要用途。另外。普利维博士带来了新的 生物标志物开发和免疫监测方面的专业知识，如所述，将成为新的 根据国际银行业发展协商小组成员的预期需要，2008年4月，卡尔顿 安德森成为新的IT核心技术员和助理总监。安德森先生提供了一个 丰富的实验室经验和专业知识。他迅速吸收了技术， 通常要求ELISAs，已接受所有现有设备的培训，并已开发，根据 Plevy博士的指导，为核心提供新的成本效益技术。 在这些人事变动的同时，IT核心的目标也发生了变化， 扩大随着中心的重点从妇科疾病转向炎症性疾病和癌症， 中心成员的需求发生了变化，IT核心获得了新的能力。从 最初为少数研究者进行的三种免疫测定，核心现在为 客户群超过50个实验室，并提供一系列复杂的服务，包括（a）超过50个 不同类型的ELISA和RIA测量，（B）定制免疫测定开发，和（c） 定量多重蛋白质组学分析，可以适用于许多应用。期间 最后一个资助周期，如本申请其他地方所述，IT的蛋白质组成分 核心被淘汰了。这一决定反映了校园中存在多个核心， 具有成本效益的蛋白质组学分析，以及随后的投票和CGIBD执行委员会的批准 世卫组织的结论是，这种技术不再是高度优先事项。 为CGIBD社区提供更广泛和更具成本效益的服务。 博士Plevy发起了新的细胞因子ELISA开发，用于最需要的细胞因子测定， CGIBD研究人员实验室的既定技术。安德森先生已经和 标准ELISA试剂盒的价格更好;因此，CGIBD研究人员立即受益于10- 提供服务的成本降低35%。 随着越来越重视转化研究，IT核心已经开始了几个 新举措。通过收购新的 技术平台和主题一致的NIH路线图，将是生物标志物 发展vnth强调对人的研究。我们现在正在进行多重蛋白质 使用xMAP技术进行分析。我们已经与第n个Bio-Rad和R & D Systems谈判， 核心的Bio-Bio 200系统的多重试剂盒的折扣价格， 和鼠类研究，并有助于生物标志物的开发。此外，我们正在计划一个 现场研讨会，以使调查人员更好地了解多路平台。我们还 与Glycominds，Inc.开发基于ELISA的血清学标记 针对人类炎症性肠病（IBD）、肠易激综合征（IBS）、 综合征（IBS）和炎症性肝病。最后，由于最近NIH资助和 在一些中心调查人员的行业赞助活动中，核心对以下方面感兴趣： IBD患者的免疫监测，包括但不限于免疫原性和疫苗 监测以及治疗干预期间的免疫活性和重建。 这项技术的开发将适用于许多胃肠道疾病，其中评估微妙的 对人类免疫系统的影响对于理解临床免疫疗法的安全性和有效性是至关重要的。 干预措施，包括疫苗接种试验，细胞疗法，药物疗法，癌症免疫疗法， 移植和自身免疫/炎性疾病。

When the UNC Center for Gastrointestinal Biology and Disease was initially established it emphasized analysis of epithelial transport, grovrth, development, and repair, including control of these functions by subepithelial immune and mesenchymal cells. From the outset, it was recognized that a Core Facility capable of measuring levels of soluble signaling molecules (such as peptide hormones, growth factors, eicosanoids, cytokines, and cyclic nucleotides) would be essential to investigators pursuing these goals. For this reason, an Immunoassay (IA) Core was established, and staffed with a Core Director (Dr. Don Powell) and a Core Technician. In 1991, Dr. Michael Goy replaced Dr. Powell as the IA Core Director. Due to steadily increasing demand for Core services, an additional half-time technician was hired in 2002. In January 2008, Scott Plevy replaced Michael Goy as IT Core Director. The strategic reason for this change was Dr. Plevy's expertise in cytokine biology and quantitative technologies, which historically has comprised the predominant usage of the core. In addition. Dr. Plevy brought new expertise in biomarker development and immune monitoring, which as described, will become new initiatives of the Core based on the prospective needs of CGIBD members. In April 2008, Carlton Anderson became the new IT Core Technician and Assistant Director. Mr. Anderson provides a wealth of laboratory experience and expertise. He has rapidly assimilated techniques for the most commonly requested ELISAs, has been trained on all existing equipment, and has developed, under the guidance of Dr. Plevy, new cost effective technologies for the Core. In parallel with these personnel changes, the objectives ofthe IT Core have also evolved and expanded. As the focus ofthe Center has shifted from diarrheal to inflammatory diseases and cancer, the needs of Center members have shifted and the IT Core has acquired new capabilities. From an initial repertoire of three immunoassays performed for a few investigators, the Core now serves a client base of over 50 laboratories, and offers a sophisticated array of services, including (a) over 50 diffierent types of ELISA and RIA measurements, (b) custom immunoassay development, and (c) quantitative multiplex proteomic analysis that can be adapted to numerous applications. During the last funding cycle, as described elsewhere in this application, the proteomic component ofthe IT Core was eliminated. This decision reflects the existence of multiple cores on campus that provide cost-eff^ective proteomic analysis, and followed polling and approval of CGIBD executive committee who concluded that such technology is no longer a high priority. To provide expanded and significantly more cost-effective services to the CGIBD community. Dr. Plevy initiated new cytokine ELISA development for the most requested cytokine assays based on established technology in CGIBD investigator's laboratories. Mr. Anderson has already negotiated better prices for standard ELISA kits; therefore, CGIBD investigators immediately benefitted by a 10- 35% reduction in costs for services provided. With increased emphasis on translational research, the IT Core has embarked upon several new initiatives. An emphasis of the IT Core moving forward, facilitated by the acquisition of new technology platforms and thematically consistent vnth the NIH Roadmap, will be biomarker development vnth an emphasis on human studies. We are now performing multiplex protein analysis using xMAP technology. We have negotiated vnth Bio-Rad and R and D Systems toreceive discounted prices on multiplex kits for the Core's Bio-Plex 200 system which vnll facilitate human and murine research, and contribute to biomarker development. Additionally, we are planning an on-site symposium to better acquaint investigators with the multiplex platform. We have also established collaboration with Glycominds, Inc. to develop ELISA-based serological markers directed against the enteric microbiota in human inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and inflammatory liver diseases. Finally, as a result of recent NIH funded and industry sponsored activities of several Center investigators, the Core has taken an interest in immune monitoring in IBD patients, including but not limited to, immunogenicity and vaccine monitoring, and immunocompetence and reconstitution during therapeutic interventions. Development of this technology will be applicable across many GI disorders where assessing subtle effects on the human immune system vnll be critical to understand safety and efficacy of clinical interventions, including trials of vaccinations, cellular therapy, drug therapy, cancer immunotherapy, transplantation, and autoimmune/inflammatory disorders.